IL293623A - Treatment of acute myeloid leukemia or myelodysplastic syndrome - Google Patents

Treatment of acute myeloid leukemia or myelodysplastic syndrome

Info

Publication number
IL293623A
IL293623A IL293623A IL29362322A IL293623A IL 293623 A IL293623 A IL 293623A IL 293623 A IL293623 A IL 293623A IL 29362322 A IL29362322 A IL 29362322A IL 293623 A IL293623 A IL 293623A
Authority
IL
Israel
Prior art keywords
compound
dose
patients
aml
treatment
Prior art date
Application number
IL293623A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of IL293623A publication Critical patent/IL293623A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL293623A 2019-12-06 2020-12-04 Treatment of acute myeloid leukemia or myelodysplastic syndrome IL293623A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962944876P 2019-12-06 2019-12-06
PCT/CA2020/051668 WO2021108918A1 (en) 2019-12-06 2020-12-04 Treatment for acute myeloid leukemia or myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
IL293623A true IL293623A (en) 2022-08-01

Family

ID=76221282

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293623A IL293623A (en) 2019-12-06 2020-12-04 Treatment of acute myeloid leukemia or myelodysplastic syndrome

Country Status (12)

Country Link
US (1) US12533357B2 (enExample)
EP (1) EP4069246A4 (enExample)
JP (1) JP2023505301A (enExample)
KR (1) KR20220124177A (enExample)
CN (1) CN115397429A (enExample)
AU (1) AU2020396807B2 (enExample)
BR (1) BR112022011052A2 (enExample)
CA (1) CA3163796A1 (enExample)
IL (1) IL293623A (enExample)
MX (1) MX2022006910A (enExample)
TW (1) TWI880995B (enExample)
WO (1) WO2021108918A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
TWI926033B (zh) 2021-05-11 2026-05-21 美商歐瑞克製藥公司 類ｐｏｌｏ激酶４抑制劑
TW202333712A (zh) * 2021-12-22 2023-09-01 加拿大健康網路大學 於急性骨髓性白血病或淋巴瘤之治療
CN117180295A (zh) * 2023-09-13 2023-12-08 华东医院 一种用于治疗tp53突变髓系肿瘤的药物组合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115279A1 (en) 2009-04-06 2010-10-14 University Health Network Kinase inhibitors and method of treating cancer with same
TWI516262B (zh) 2010-04-06 2016-01-11 健康網路大學 激酶抑制劑及以其治療癌症的方法
CA2803446C (en) * 2010-07-02 2019-06-04 University Health Network Use of plk4 antagonists for treating pten mutant diseases
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
EP3052102B1 (en) 2013-10-04 2019-12-04 Aptose Biosciences Inc. Compositions for treating cancers
TR201902875T4 (tr) * 2013-10-18 2019-03-21 Univ Health Network Plk-4 inhibitörünün tuz ve kristal formları.
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
KR20190129889A (ko) 2017-03-31 2019-11-20 노파르티스 아게 혈액 종양에서 HDM2-p53 상호작용 억제제의 용량 및 요법
JP7343483B2 (ja) * 2017-09-08 2023-09-12 ユニバーシティー ヘルス ネットワーク Ｐｏｌｏ様キナーゼ４の阻害のための併用療法
US11612604B2 (en) * 2017-12-06 2023-03-28 Ludwig Institute For Cancer Research Ltd Methods of treating cancer with PLK4 inhibitors
EP3959209A4 (en) 2019-04-24 2022-12-28 University Health Network S4 CRYSTALLINE FORM OF A PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1H-IMIDAZOL-6-YL )-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE

Also Published As

Publication number Publication date
AU2020396807A1 (en) 2022-07-21
JP2023505301A (ja) 2023-02-08
US12533357B2 (en) 2026-01-27
EP4069246A1 (en) 2022-10-12
MX2022006910A (es) 2022-11-09
US20230010772A1 (en) 2023-01-12
CA3163796A1 (en) 2021-06-10
CN115397429A (zh) 2022-11-25
BR112022011052A2 (pt) 2022-08-16
EP4069246A4 (en) 2023-12-06
WO2021108918A1 (en) 2021-06-10
TW202134237A (zh) 2021-09-16
AU2020396807B2 (en) 2026-07-16
TWI880995B (zh) 2025-04-21
KR20220124177A (ko) 2022-09-13

Similar Documents

Publication Publication Date Title
US12533357B2 (en) Treatment for acute myeloid leukemia or myelodysplastic syndrome
JP2012515184A (ja) 大腸がんの治療方法
US20160243124A1 (en) Method for treating acute myeloid leukemia
JP7611855B2 (ja) ユーイング肉腫治療用キノリン系化合物又はその薬学的に許容される塩
JP7266030B2 (ja) リンパ球悪性疾患を治療するための方法
AU2012321110A1 (en) Combination treatment
WO2015006822A1 (en) Method of pre-preparing medications for therapeutic uses
EP3703755A1 (en) Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors and methods of use
CN113329749B (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
US20230132982A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
TWI849001B (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
CN113509475A (zh) Bcl-2/bcl-xl抑制剂的组合及相关用途
CA3245251A1 (en) TREATMENT METHOD COMPRISING KRAS G12C INHIBITORS AND SHP2 INHIBITORS
EA049792B1 (ru) Лечение острого миелоидного лейкоза или миелодиспластического синдрома
IL300145A (en) A combination of a BCL-2 inhibitor and a hypomethylating agent for the treatment of cancer, its uses and pharmaceutical preparations
US20240335440A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor
JP2026510567A (ja) 血液悪性腫瘍の治療におけるロギノリシブ及びｂｃｌ－２阻害剤の組み合わせ
HK40085748A (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
HK1069983A1 (en) Compositions comprising epothilones and their use for the treatment of the carcinoid syndrome